I-Mab Biopharma racks up $220 mln Series C

Shanghai-based I-Mab Biopharma, which focuses on biologics in therapeutic areas of immuno-oncology and immuno-inflammation, has closed $220 million in Series C funding. Hony Capital led the round with participation from Hillhouse Capital, HOPU Investments, CDH Investment, Ally Bridge Group, EDBI, C-Bridge Capital and Tasly Capital. China Renaissance served as financial adviser on the transaction.

Source: Press Release